| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |